Published online August 1, 2006
PEDIATRICS Vol. 118 No. 2 August 2006, pp. e421-e429 (doi:10.1542/peds.2006-0287)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singleton, R.
Right arrow Articles by Butler, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singleton, R.
Right arrow Articles by Butler, J. C.
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Haemophilus influenzae Infections

ARTICLE

The Alaska Haemophilus influenzae Type b Experience: Lessons in Controlling a Vaccine-Preventable Disease

Rosalyn Singleton, MD MPHa,b, Laura Hammitt, MDa,b, Thomas Hennessy, MD, MPHa, Lisa Bulkow, MSa, Carolynn DeByle, BSa, Alan Parkinson, PhDa, Tammy E. Cottle, BAa, Helen Peters, RNa and Jay C. Butler, MDa

a Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska
b Alaska Native Tribal Health Consortium, Anchorage, Alaska

OBJECTIVE. Before 1991, Alaska Native children experienced one of the highest rates of invasive Haemophilus influenzae type b disease. H influenzae type b vaccine has led to a near-elimination of invasive H influenzae type b disease in the United States. We describe challenges encountered in controlling H influenzae type b disease in Alaska and update the current status of H influenzae disease and carriage in Alaska as lessons to other populations.

PATIENTS AND METHODS. We reviewed data from statewide H influenzae disease surveillance conducted during 1980–2004. Vaccine coverage data were based on audits from tribal facilities and the National Immunization Survey. H influenzae type b colonization data were based on 6 carriage studies.

RESULTS. After universal infant vaccination in 1991, H influenzae type b disease among Alaska Native and non-Native children <5 years of age decreased by 94% and 96%, respectively. After a 1996 change in H influenzae type b vaccine from polyribosylribitol phosphate-outer membrane protein conjugate vaccine to H influenzae type b oligosaccharide-CRM197 vaccine, the incidence of H influenzae type b disease increased in rural Alaska Natives from 19.8 to 91.1 cases per 100000 per year <5 years of age. During 2001–2004, with use of polyribosylribitol phosphate-outer membrane protein conjugate vaccine, the rate of H influenzae type b disease in Alaska Native and non-Native children aged <5 years decreased to 5.4 and 0 per 100000 per year, respectively. In postvaccine studies, H influenzae type b carriage has decreased in Alaska Native children <5 years of age.

CONCLUSIONS. H influenzae type b vaccination has resulted in a dramatic decrease in invasive H influenzae type b disease in Alaska; however, despite high rates of H influenzae type b vaccine coverage, H influenzae type b disease rates among rural Alaska Native children <5 years of age remain higher than the rates among non-Native Alaska and other US children. Equity in disease rates may not be achieved in indigenous populations with the current vaccines unless other environmental and household factors contributing to disease transmission are addressed.

Key Words: Haemophilus influenzae type b • vaccine • Alaska Native children

Abbreviations: Hib—Haemophilus influenzae type b • CDC—Centers for Disease Control and Prevention • AIP—Arctic Investigations Program • TVF—true vaccine failure • ANTHC—Alaska Native Tribal Health Consortium • PRP—polyribosylribitol phosphate • HbOC—Haemophilus influenzae type b oligosaccharide-CRM197 vaccine • OMP—outer membrane protein conjugate vaccine • CI—confidence interval

Accepted Mar 23, 2006.




This article has been cited by other articles:


Home page
 CVIHome page
P. Gomez-de-Leon, F. J. Diaz-Garcia, A. Villasenor-Sierra, J. Segura, M. I. Carranza, J. L. Arredondo-Garcia, and J. I. Santos
Immunoglobulin G Avidities in Infants in Mexico after Primary Immunization with Three Doses of Polyribosylribitol Phosphate-Tetanus Toxoid Haemophilus influenzae Type b Vaccine
Clin. Vaccine Immunol., June 1, 2008; 15(6): 1024 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
S. W. Satola, J. T. Collins, R. Napier, and M. M. Farley
Capsule Gene Analysis of Invasive Haemophilus influenzae: Accuracy of Serotyping and Prevalence of IS1016 among Nontypeable Isolates
J. Clin. Microbiol., October 1, 2007; 45(10): 3230 - 3238.
[Abstract] [Full Text] [PDF]